David Baldwin is Professor of Psychiatry and Head of the Mental Health Group in the Clinical and Experimental Sciences Academic Unit of the Faculty of Medicine at the University of Southampton in the UK. He is President-Elect of the British Association for Psychopharmacology, Past President of Depression Alliance, a Medical Patron of Anxiety UK, Editor-in-Chief of Human Psychopharmacology, and author of over 300 articles in peer-reviewed scientific journals.
He aims to improve clinical outcomes in mood and anxiety disorders: by investigating the role of neurobiological and psychological factors in causing and maintaining illness; through improving trial design when evaluating efficacy and tolerability of treatment interventions; by assessing the effectiveness and acceptability of treatment interventions in wider clinical practice; through identifying more accurately those patient groups at particular risk of poor outcomes.
In recognition of Professor Malcolm Lader, past President of the SSA and past President of the British Association for Psychopharmacology
Malcolm H. Lader PhD MD DSc FMedSci FRCPsych LLB OBE
Professor of Clinical Psychopharmacology, Institute of Psychiatry
President of Society for Study of Addiction, 1983-1993
President for British Association for Psychopharmacology 1986-1988
First drew attention to problems with benzodiazepines in 1972.
Characterised features of and risk factors for benzodiazepine dependence syndrome.
Dedication to raising awareness of balance of risk and benefit.
Concerned about emerging data relating to gabapentinoids.
Patient experiences and perceptions of benzodiazepines and Z-drugs: lessons for safer prescribing , Dr Coral Sirdifield (University of Lincoln, UK)
Gabapentinoid prescriptions – what should we learn from the insights of Malcolm Lader?, Professor Maryse Lapeyre-Mestre (Université de Toulouse, France)